Business Wire

Corindus, A Siemens Healthineers Company, Announces Study Results Demonstrating Safety and Effectiveness of CorPath® GRX Neurovascular System

Share

Corindus, A Siemens Healthineers Company and a leading developer of precision vascular robotics, announced today it presented the results of a first-of-its-kind study demonstrating the safety and effectiveness of robotic-assisted neurovascular aneurysm embolization using the CorPath GRX Neurovascular System. The data represents a milestone in the company’s commitment to extending precision robotics into neurovascular treatment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220907006221/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

CorPath GRX Neurovascular System (Photo: Business Wire)

The prospective, single-arm, international, multi-center, non-inferiority study is the world’s first trial on robotic-assisted neurovascular aneurysm embolization. Principal Investigator Michel Piotin, MD, PhD, Head of the Interventional Neuroradiology Department at the Rothschild Foundation Hospital in Paris, presented the results as part of the AI & New Innovations session at the European Society of Minimally Invasive Neurological Therapy (ESMINT) Congress in Nice, France. Key findings of the study showed:

  • The CorPath GRX Neurovascular System demonstrated 94 percent technical success. It achieved the primary effectiveness goal, which was defined as successful completion of the robotic-assisted endovascular procedure absent of any unplanned conversion to a manual procedure.
  • The CorPath GRX Neurovascular System demonstrated 95.7 percent clinical success. It achieved the primary safety goal, defined as patients treated without intra- and periprocedural adverse events, including target aneurysmal rupture, vessel perforation or dissection, and thromboembolic event with neurological decline within 24 hours post-procedure or hospital discharge, whichever occurred first.
  • 64.5 percent of subjects achieved Class I status, meaning complete obliteration of the aneurysm, on the Raymond-Roy Occlusion Classification (RROC), the standard for evaluating aneurysm occlusion.
  • 78.2 percent of subjects showed no clinical symptoms post-procedure, achieving a 0 on the Modified Rankin Scale (mRS) for Neurologic Disability. The remaining 21.8 percent of subjects had an mRS of 1 or 2.

“Neurovascular intervention demands extreme precision to achieve optimal clinical outcomes,” said Dr. Piotin. “The results of the study show the CorPath GRX System helps physicians move efficiently within tortuous and unstable vessels. I am honored to have participated in a groundbreaking study that may lead to an entirely new treatment paradigm in neurovascular care.”

The study included 117 patients from 10 clinical sites in six different countries. It also included a wide range of aneurysms, representing a diverse collection of cases with different locations, sizes and morphology characteristics. The healthcare facilities that treated the trial participants will follow them for 180 days to monitor extended, long-term outcomes.

“The work of our clinical partners on this study marks an early step toward truly transformative change in neurovascular intervention,” said Dr. Raymond Turner, Chief Medical Officer, Neuroendovascular at Corindus. “By incorporating robotic platforms in this space, we are paving the way for remote interventional procedures in the future that will connect patients to specialized interventionalists for treatment, regardless of location. Validating clinical evidence, such as this study, will serve as the foundation for that transformation.”

The CorPath GRX System is the first FDA-cleared and CE Marked medical device for percutaneous coronary and vascular procedures. It earned CE Mark for neurovascular procedures, and healthcare facilities outside of the U.S. currently utilize the platform for neurovascular interventions. The company is currently pursuing additional regulatory clearances for the neurovascular indication.

To learn more about CorPath GRX, please visit www.corindus.com.

ABOUT CORINDUS

Corindus, A Siemens Healthineers Company, is a global technology leader in robotic-assisted vascular interventions. The Company’s CorPath® platform is a medical device to bring robotic precision to percutaneous coronary and vascular procedures. CorPath GRX is the second-generation robotic-assisted technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. We are focused on developing innovative robotic solutions to revolutionize treatment of emergent conditions by providing specialized and timely medical care to patients around the world. For additional information, visit www.corindus.com, and follow @CorindusInc.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Matter Health for Corindus
Jill Gross
+1 978-518-4258
corindus@matternow.com

Siemens Healthineers, North America
Jeffrey Bell
+1 484-868-8346
Jeffrey.t.bell@siemens-healthineers.com

Siemens Healthineers, Europe
Kathrin Palder
+49 173-3645319
kathrin.palder@siemens-healthineers.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Global CIOs geared up to scale AI but organizations aren’t as ready25.4.2024 05:00:00 CEST | Press release

AI is the CIO’s top priority, according to findings of Lenovo’s third annual global CIO report. Inside the Tornado: How AI is Reshaping Corporate IT Today, reveals that while CIOs need to adopt and scale AI urgently, their ambitions are threatened by speed, security, and other organizational functions lagging in AI readiness. In a stark contrast to previous years, CIOs are tabling non-traditional responsibilities to sharpen their focus on core IT functions. Slightly more than half (51%) of CIOs feel AI/ML is an urgent priority to address, matched only by cybersecurity. This urgency is directly correlated to the pressure that CIOs are under to drive business impact, rather than operational maintenance and preservation. 84% of CIOs revealed they are being evaluated on business outcome metrics more than ever before. “Today’s CIOs are working in a tornado of innovation. After years of IT expanding into non-traditional responsibilities, we’re now seeing how AI is forcing CIOs back to their

Mundipharma acquires all assets and rights related to REZZAYO ® (rezafungin) , reinforcing continued commitment to management of infectious diseases and specialty care therapeutic area24.4.2024 22:01:00 CEST | Press release

Mundipharma* today announced the acquisition of all assets and rights related to rezafungin globally from Cidara Therapeutics. This provides Mundipharma with global ownership of rezafungin including ongoing development and distribution. Rezafunginis a novel once-weekly echinocandin indicated for the treatment of invasive candidiasis in adults.1 Invasive candidiasis, is a severe, life-threatening infection of the bloodstream and/or deep/visceral tissues.2,3 It affects seriously ill people, especially those with a weakened immune systemand the mortality rate can be 40%4 or more.5,6 It can place a large burden on the healthcare system, with the potential for extended treatment regimens and long hospital stays.6 Over the last 15 years, there have been no new treatments and morbidity and mortality rates remain largely the same, indicating the need for alternative treatment options.7,8 “This acquisition places Mundipharma in the best position to realise the full potential of rezafungin inclu

Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting24.4.2024 22:01:00 CEST | Press release

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share research outcomes from its broad hematology and solid tumor portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 - June 4, 2024. “Our presentations at this year’s ASCO highlight the strength of our growing oncology portfolio and our commitment to developing treatments that address the unmet needs of patients with B-cell malignancies and solid tumors,” Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene. “The exciting data we will share during ASCO showcase BRUKINSA’s uniquely differentiated clinical profile and add to the growing body of evidence supporting its role across the blood cancer treatment paradigm.” BeiGene will share new data for BRUKINSA (zanubrutinib), which add to the robust efficacy and safety evidence differentiating it within the BTK class. Key highlights include: A network meta-analysis co

TSMC Celebrates 30 th North America Technology Symposium with Innovations Powering AI with Silicon Leadership24.4.2024 21:30:00 CEST | Press release

TSMC (TWSE: 2330, NYSE: TSM) today unveiled its newest semiconductor process, advanced packaging, and 3D IC technologies for powering the next generation of AI innovations with silicon leadership at the Company’s 2024 North America Technology Symposium. TSMC debuted the TSMC A16TM technology, featuring leading nanosheet transistors with innovative backside power rail solution for production in 2026, bringing greatly improved logic density and performance. TSMC also introduced its System-on-Wafer (TSMC-SoW™) technology, an innovative solution to bring revolutionary performance to the wafer level in addressing the future AI requirements for hyperscaler datacenters. This year marks the 30th anniversary of TSMC’s North America Technology Symposium, and more than 2,000 attended the event, growing from less than 100 attendees 30 years ago. The North America Technology Symposium in Santa Clara, California kicks off TSMC Technology Symposiums around the world in the coming months. The symposiu

Rimini Street Appoints Steve Hershkowitz as Chief Revenue Officer24.4.2024 18:50:00 CEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, products, and services, the leading third-party support provider for Oracle and SAP software, and a Salesforce and AWS partner, today announced the appointment of Steve Hershkowitz as its new Chief Revenue Officer (CRO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424061249/en/ Rimini Street Appoints Steve Hershkowitz as Chief Revenue Officer (Photo: Business Wire) “Steve’s leadership and extensive experience scaling businesses to deliver top-line growth will expand our sales reach to capture new logos and increase our opportunity to provide even greater value to our clients,” said Rimini Street president and CEO Seth Ravin. “The global revenue team and I are excited to work closely together with Steve to drive growth and broader capabilities for our company.” Leading the Next Chapter of Sales Growth and Continued Success f

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye